The serotonin 5-HT 2A receptor is suspected to be involved in a number of psychiatric disorders, including schizophrenia. In particular, atypical antipsychotics have antagonistic effects on the 5-HT 2A receptors, supporting a specific role of the 5-HT 2A receptor in the pathophysiology of this disease. The aim of this study is to investigate cortical and subcortical 5-HT 2A binding in neuroleptic-naive schizophrenic patients. Fifteen neuroleptic-naive patients diagnosed with schizophrenia (age 27.5 ± 4.5 years), 11 men and 4 women, and 15 healthy control subjects matched for age (28.5 ± 5.7 years) and gender underwent a 40 min positron emission tomography (PET) study using the 5-HT 2A antagonist, [18 F]altanserin, as a radioligand. PET images were co-registered to 3 T magnetic resonance images (MRIs) for each individual subject, and ROIs were applied automatically onto the individual MRIs and PET images. The cerebellum was used as a reference region. The binding potential of specific tracer binding (BP p ) was used as the outcome measure. No significant difference was seen in cortical receptor distribution between patients and controls. An increase in 5-HT 2A receptor binding in the caudate nucleus was detected in the group of schizophrenic patients (0.7 ± 0.1) when compared to the healthy controls (0.5 ± 0.3) (p ¼ 0.02). Our results confirm other in vivo findings of no difference in cortical 5-HT 2A receptor binding between first-episode antipsychotic-naive schizophrenic patients and age-and gender-matched healthy control subjects. However, a preliminary finding of increased 5-HT 2A binding in the caudate nucleus requires further investigation to explore the relation of subcortical and cortical 5-HT 2A receptor binding.